Clinical Trials
34 trialsNCT01804686 2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05006716 2026-06-03
CaDAnCe-101
BeOne Medicines
Phase 1/2 Recruiting
NCT06742996 2026-06-03
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
Phase 3 Recruiting
NCT05753501 2026-06-02
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Phase 1 Active not recruiting
NCT02972840 2026-06-01
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT05951959 2026-06-01
TrAVeRse
AstraZeneca
Phase 2 Active not recruiting
NCT05458297 2026-05-29
MK-2140-006
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT07609862 2026-05-27
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2 Not yet recruiting
NCT02213926 2026-05-18
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
Phase 2 Active not recruiting
NCT04002297 2026-05-18
MANGROVE
BeOne Medicines
Phase 3 Active not recruiting
NCT04662255 2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT06564038 2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT02362035 2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT07101328 2026-05-13
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07029737 2026-05-07
SOUND-MCL
AstraZeneca
Phase 2 Recruiting
NCT07569965 2026-05-06
FRONTIER
Miltenyi Biomedicine GmbH
Phase 2 Not yet recruiting
NCT06542250 2026-05-01
TITANium
AstraZeneca
Phase 1/2 Recruiting
NCT07082686 2026-04-27
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2 Recruiting
NCT02717624 2026-04-20
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Acerta Pharma BV
Phase 1 Active not recruiting
NCT03932331 2026-04-20
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
AstraZeneca
Phase 1/2 Active not recruiting
NCT05020678 2026-04-20
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
Phase 1 Active not recruiting
NCT05294731 2026-04-17
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
Phase 1/2 Recruiting
NCT04329728 2026-04-15
OPAL
AVM Biotechnology Inc
Phase 1/2 Recruiting
NCT05131022 2026-04-14
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT04911478 2026-04-09
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Adicet Therapeutics
Active not recruiting
NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
NCT04903197 2026-04-01
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
NCT06533579 2026-03-30
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT04830137 2026-03-20
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
NCT06561425 2026-03-16
Atalanta-1
Lakefront Biotherapeutics NV
Phase 1/2 Active not recruiting